the definition. The odds of declining were significantly reduced for donepezil-treated versus placebo patients (p ! 0.0001; all definitions). Among patients meeting criteria for clinical worsening, mean declines in MMSE scores were greater for placebo than donepezil-treated patients. Conclusion: In this population, donepezil treatment was associated with reduced odds of clinical worsening of AD symptoms. Moreover, patients worsening on donepezil were likely to experience less cognitive decline than expected if left untreated. This suggests that AD patients showing clinical worsening on donepezil may still derive benefits compared with placebo/untreated patients.
problems [1] . Despite the progressive nature of AD, it is frequently assumed that treatment benefits in patients can be demonstrated only by an improvement or stabilization of cognitive, functional and/or behavioral symptoms. In support of this notion, authorities tend to license AD therapy and provide guidance on the use of this therapy based on demonstrable symptomatic improvements [2] . However, while improvement and, to a lesser extent, stabilization are ideal outcomes of treatment, therapeutic end points based on reduced worsening or less than expected decline are also clinically relevant and, at present, potentially more realistic goals for patients suffering from progressive dementia [3] [4] [5] .
The cholinesterase inhibitor donepezil is licensed for the treatment of mild to moderately severe AD in many countries worldwide and has been approved for the treatment of severe AD in several countries, including the USA. In randomized, double-blind, placebo-controlled clinical trials, donepezil has been shown to provide benefits in cognition, function and behavior in patients with mild-tomoderate, moderate-to-severe and severe AD [6] [7] [8] [9] [10] [11] [12] . As with all dementia therapy, some patients treated with donepezil do not show an improvement or stabilization of symptoms. These patients may initially be characterized as unresponsive to treatment, but some may still show less of a decline than would be expected if left untreated. The failure to identify this effect may result not only from perceptions regarding what constitutes a positive outcome in AD, but also from the difficulty in measuring a less than expected decline in an individual patient.
Useful information regarding the relevance of response definitions in patients with AD may be provided by 'responder' analyses. These analyses allow identification of patient subpopulations meeting specific 'response' criteria and, thus, facilitate evaluation of various outcomes within these subpopulations. Previous responder analyses have tended to focus on positive outcomes of treatment in patients receiving AD therapy [13] and have therefore focused on improvement in cognitive and/or functional and global measures. However, this does not take into account the continued progression of the disease in the majority of patients. In addition, an important treatment benefit may be overlooked if the possibility of reduced clinical worsening is not considered as a potential treatment goal in the setting of a progressive degenerative disease.
In an attempt to assess the utility of treatment in preventing/delaying the worsening of clinical symptoms in AD patients, we performed an analysis in which 'response' was considered not as improvement, but as reduced worsening. In this type of analysis, patients receiving placebo would be expected to respond less, that is worsen more, than patients under active therapy. We investigated whether donepezil-treated patients with mild-to-moderate AD are less likely to experience clinical worsening compared with placebo patients. An additional objective was to determine, in those patients meeting similar criteria for clinical worsening, whether donepezil-treated patients show a reduced degree of cognitive decline compared with those on placebo. For the current analyses, several criteria were used to define clinical worsening based on concurrent decline on commonly used scales assessing cognition, global outcomes and function. The overall purpose was to provide greater insight into the range of responses to donepezil, particularly in patients without symptomatic stabilization or improvement.
Methods

Study Selection
Studies were selected for inclusion in the present analyses if they met the following prespecified criteria: (1) a randomized, double-blind, placebo-controlled parallel-group study of the use of donepezil in the treatment of AD; (2) conducted within the donepezil clinical development program and with available individual patient level data; (3) at least 24 weeks in duration; (4) available postbaseline cognition data as measured by the Mini-Mental State Examination (MMSE) [14] ; (5) available postbaseline global data as measured by the Clinician's Interview-Based Impression of Change plus Caregiver Input (CIBIC+) [15] or the GottfriesBråne-Steen (GBS) scale [16, 17] , and (6) available postbaseline function data measured using any functional scale. In total, 3 studies met the prespecified inclusion criteria and were included in the subsequent analyses ( table 1 ). One study was conducted at multiple sites in the USA (302 study), 1 at sites throughout northern Europe (Nordic study) and 1 at sites in Canada, Australia and France [Moderate to Severe AD (MSAD) study]. Detailed descriptions of study designs for the individual trials have been published previously [7, 10, 11] . The 302 and Nordic studies enrolled patients with baseline MMSE scores of 10-26, whereas the MSAD study enrolled patients with MMSE scores of 5-17. To limit the current analyses to a population with mild-to-moderate AD, individual patient data were pooled only from the subset of patients with baseline MMSE scores of at least 10.
Patients
All patients enrolled in the original trials had a diagnosis of possible or probable AD based on criteria of the National Institute of Neurological and Communicative Disorders and Stroke -Alzheimer's Disease and Related Disorders Association [18] . Patients enrolled in the 302 and Nordic studies were also required to meet criteria for dementia of Alzheimer's type from the third or fourth edition of the Diagnostic and Statistical Manual of Mental Disorders [19] . In general, inclusion/exclusion criteria were similar across the 3 studies [7, 10, 11] . In the 302 study, patients were ran-domized to either donepezil 5 mg/day, donepezil 10 mg/day or placebo. A blinded, forced-dose escalation method was used for the higher-dose group, in which subjects received 5 mg/day for 1 week and then 10 mg/day for the remainder of the study. In the Nordic and MSAD studies, donepezil was given at 10 mg/day following 4 weeks of treatment with the dose 5 mg/day. In the Nordic and MSAD studies, a dose adjustment back to 5 mg/day was allowed at any time to improve tolerability, if required. All studies were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice.
Outcome Measures
All 3 studies used the MMSE to measure cognition. The MMSE is a brief psychometric test that evaluates the cognitive status of the patient and includes aspects of memory, orientation, language and praxis. Scores range from 0 to 30, with lower scores indicating greater cognitive impairment. In the 302 study, cognition was also assessed using the Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog) [20] .
In the 302 and MSAD studies, global outcomes were assessed using the CIBIC+. The 302 study also assessed global outcomes using the Clinical Dementia Rating Sum of the Boxes (CDR-SB) [21] . In the Nordic study, global outcomes were assessed using the GBS scale, as well as the Global Deterioration Scale [22, 23] .
Function was assessed in the Nordic study using the Progressive Deterioration Scale (PDS) [23] and in the MSAD study using the Disability Assessment for Dementia [24] , the modified Instrumental Activities of Daily Living scale and the Physical SelfMaintenance Scale [26] . Function was not formally assessed in the 302 study but could be evaluated via 3 domains of the CDR-SB that are comparable to domains measured in most ADL scales (i.e. community affairs, home and hobbies, personal care).
Behavior was assessed in the Nordic and MSAD studies using the Neuropsychiatric Inventory [27] . Behavior was not assessed in the 302 study.
In all studies, efficacy measures were utilized at weeks 12 and 24.
Definitions of Clinical Worsening
Three sets of criteria were used to define clinical worsening at week 24:
• cognition (COG): decline in cognitive function; for all patients, the criterion for this definition was any decline in MMSE;
• cognition + global (COG + G): decline in cognition and global ratings; for patients in the 302 and MSAD studies, criteria for this definition were any decline in MMSE and any decline on the CIBIC+; for patients in the Nordic study, criteria were any decline in MMSE and any decline on the GBS;
tion, global ratings and function; for patients in the 302 study, criteria for this definition were any decline in MMSE and any decline on the CIBIC+ and any decline in the sum of the 3 function-related domains of the CDR-SB (community affairs, home and hobbies and personal care); for patients in the Nordic study, criteria were any decline in MMSE and any decline on the GBS and Global Deterioration Scale and PDS; for patients in the MSAD study, criteria were any decline in MMSE and any decline on the CIBIC+ and any decline on the Instrumental Activities of Daily Living scale and Disability Assessment for Dementia and Physical Self-Maintenance Scale. A behavioral outcome was not included within the selected definitions of clinical worsening because the 302 study did not include a measure of behavior, and therefore sample sizes available for analysis would have been limited. In addition, subjects for these studies were not selected for the presence of behavioral problems.
Statistical/Data Analyses
Initial analyses focused on determining the proportion of the overall population who met the specified criteria for each definition of clinical worsening at week 24. Analyses were performed using both the last observation carried forward (LOCF) and observed cases (OC) methods. For the OC analyses, patients showing any change (improvement or worsening) in any of the 3 domains (cognition, global or function) were included in the analysis population, even if data were missing for the other domains. 2 tests were used to compare the proportion of patients meeting criteria for clinical worsening between the donepezil and placebo groups. Subsequent analyses assessed the mean change in MMSE scores from baseline to weeks 12 and 24 among patients meeting the criteria for clinical worsening. These analyses are reported using the OC method only. All analyses were based on the intent-to-treat population, defined as patients who took at least 1 dose of study medication and provided at least 1 postbaseline efficacy assessment. The random effects model, with study as random effect and baseline value and treatment as fixed effects, was used in the analyses. 
Results
Patient Population
In total, 1,049 patients were randomized to donepezil or placebo in the original trials and were assessed for eligibility for inclusion in the current analyses. From this population, 906 patients (388 receiving placebo; 518 receiving donepezil) had baseline MMSE scores 6 10 and available postbaseline data and were included in the current analyses.
Population Demographics
Patient characteristics for the analysis population are shown in table 2 . No clinically relevant differences were noted between the donepezil-treated and placebo populations.
Analysis Outcomes
A significantly greater percentage of placebo patients than donepezil-treated patients met the specified criteria for all 3 definitions of clinical worsening ( fig. 1 ; table 3 ) . In both the OC and LOCF analyses, the odds ratios for clinical worsening were significantly reduced for donepezil-treated patients compared with placebo patients (p ! 0.0001 for all definitions using OC and LOCF methods; table 3 ). As expected, as the definition criteria became more stringent, the percentage of patients with clinical worsening became smaller, irrespective of treatment allocation.
In subgroups of patients with milder (MMSE, 18-26) and more moderate AD (MMSE, 10-17), the pattern of treatment benefit mirrored that seen for the overall population. In both subgroups, the percentage of placebo patients showing clinical worsening was significantly greater than the percentage of donepezil-treated patients meeting the same criteria ( fig. 2 ) . For the most stringent definition of clinical worsening (COG + G + F), more than twice as many placebo patients as donepezil-treated patients met the specified criteria (milder subgroup, 21.3 vs. 7.2%; more moderate subgroup, 30.9 vs. 14.4%). Regardless of the definition of clinical worsening employed or the treatment allocation, the percentage of patients showing clinical worsening was greater in the more moderate subgroup than the milder subgroup.
The COG criterion for clinical worsening was defined as any decline in MMSE score. However, analysis of the degree of cognitive decline in patients who met criteria for clinical worsening showed that placebo patients tended to decline by a greater extent over the 6-month study period compared with their donepezil-treated counterparts ( table 4 ). In the week 12 and week 24 OC analyses, MMSE scores worsened by a significantly greater degree in placebo patients meeting criteria for the COG and COG + G definitions. Among patients meeting criteria for the most stringent definition (COG + G + F), mean declines in MMSE score from baseline to week 12 and week 24 were numerically greater for placebo patients, but the betweentreatment differences did not reach statistical significance ( table 4 ) .
Discussion
While the 3 original trials showed significant benefits for many patients treated with donepezil by traditional measures of improvement [7, 10, 11] , the current pooled data approach demonstrated the benefits of donepezil in reducing the worsening of cognition, global outcomes and function in patients with mild-to-moderate AD. In this pooled population, there was a significant difference in the course of the measured symptoms of the disease between donepezil-treated patients and those treated with placebo, with a significantly greater proportion of placebo patients showing clinical worsening over the 6-month study period. This outcome was also apparent when milder (MMSE, 18-26) and more moderate (MMSE, 10-17) subgroups were analyzed separately. In both the overall population and the 2 separate subgroups, the percentage of donepezil-treated patients who showed com- bined worsening on combined measures of cognition, global outcomes and function was less than half that of the patients receiving placebo. The outcomes presented here extend findings of previous studies showing positive effects of antidementia therapy on clinical worsening of symptoms in patients with AD [4, 28, 29] . In a study by Lopez et al. [29] , 60% of patients treated with cholinesterase inhibitors were classified as 'slow progressors', defined as patients showing a decline of ^ 2 points on the MMSE over 1 year. In contrast, only 30% of untreated patients were classified as 'slow progressors'. Furthermore, in a previous study of the effects of the cholinesterase inhibitor rivastigmine on preventing decline in each individual symptom domain (cognition, global and ADL), the authors reported that only 22% of patients in the high-dose rivastigmine range (6-12 mg) worsened by 4 points on the ADAS-cog over 6 months compared with 36% receiving placebo [28] . Unlike the current analyses, the study reported by Raskind et al. [28] did not incorporate a composite, multidomain definition, but separately showed reduced levels of decline in the global assessment (CIBIC+) and in a measure of functional impairment (PDS). The study concluded that the benefits of AD therapy should be seen in the context of the progressive nature of this condition and that benefit may be obtained not only from improvement, but also from stabilization and reduced worsening of symptoms.
Analyzing single domains may be confounded by fluctuations in test performance. A more robust assessment has previously been undertaken in a pooled analysis of 6 randomized controlled trials of memantine in mild-tosevere AD [4] . As in the current analyses, the memantine study used a more exacting definition of worsening across multiple domains. In the memantine study, patients were deemed to have shown marked clinical worsening if they demonstrated a worsening in functional and global assessments and had deteriorated by 6 4 points on the ADAS-cog (mild-to-moderate studies) or 6 5 points on the Severe Impairment Battery (moderate-to-severe studies). Results showed that about twice as many placebo patients (21%) showed this marked and clinically significant deterioration compared with those taking memantine (11%). The strength of analyzing the combination of assessments lies in the use of all available information in the key domains of AD to determine whether the patient is worsening or not.
The current analyses also indicated that donepeziltreated patients who met criteria for clinical worsening tended to show a lesser degree of cognitive decline compared with placebo patients meeting the same criteria of clinical worsening. For the COG and COG + G definitions, the difference in the degree of decline was statistically significant in favor of donepezil at both week 12 and week 24; for the most stringent composite definition, including a combined decline in COG + G + F, the trend p values are based on an analysis of random effects model with study as random effect and baseline value and treatment as fixed effects using a 2-tailed t test, and least significant difference procedure for pairwise comparisons. NS = Non significant (p > 0.05).
continued toward a less than expected cognitive decline with donepezil treatment but was not statistically significant.
Interestingly, there was almost no difference in the magnitude or significance of the difference between the treatment groups in the OC or LOCF analyses. In this study, which is examining worsening rather than improvement, imputed values from an earlier time point are likely to have worsened less than observed values at the end of the study. Therefore, imputing those values did not have the commonly observed effect of decreasing the effect size in the LOCF analysis. Similarly, the magnitude of the difference between the groups of the least squares mean change in MMSE score among those who met criteria for clinical worsening was notably greater at 12 weeks than at 24 weeks, indicating a greater effect of donepezil on MMSE score at 12 weeks compared to 24 weeks ( table 4 ) . This extends the finding of a peak effect of donepezil on MMSE scores at 12-18 weeks that has previously been observed in donepezil AD clinical trials [7, 10, 11] .
A potential weakness of the current analysis is that although the included studies used a standardized measure of cognition, i.e. the MMSE, they used different scales to measure global and functional responses. As a result, the criteria used for the COG + G and COG + G + F definitions of clinical worsening varied among the 3 studies and the relative sensitivity to change of these different scales criteria is unclear. However, since the criteria were equally applied to the donepezil-treated and placebo patient groups, statistical comparisons between these patient populations remain valid.
In conclusion, the current analyses demonstrated that during the mild-to-moderate stages of AD significantly fewer patients treated with donepezil experienced symptomatic worsening compared with those receiving placebo. Moreover, patients who did worsen while receiving donepezil were likely to experience less cognitive decline than would be expected if left untreated. These results suggest that many donepezil-treated patients initially characterized as 'nonresponders' according to traditional markers of treatment success (i.e. those based on improvement) may still derive benefits over placebo/untreated patients. Moreover, results from the current analyses, as well as previous related studies [4, 28, 29] suggest that assessment of treatment benefit, both in clinical trials and in the clinic, should include end points based on reduced worsening and less than expected decline to effectively assess the range of benefits of antidementia therapy.
